Liquidia reports Q3 2026 loss driven by $389.7 M litigation settlement but revenue beats estimates
Liquidia Corporation posted a GAAP net loss of $236.3 million ($2.64 per share) for Q3 2026, primarily because of a $389.7 million charge to settle six lawsuits with United Therapeutics. Revenue rose 314% year‑over‑year to $225.3 million, with YUTREPIA product sales of $222.7 million, up 31% from the prior quarter. Adjusted EBITDA reached $140.5 million, marking the fifth consecutive quarter of growth. The company said it will fund the $380.7 million settlement installments from cash and ongoing YUTREPIA sales.
Why it matters
The settlement creates a large cash outflow but the company’s cash balance of $396.1 million provides liquidity to meet the payments. Revenue beat and strong commercial metrics suggest the underlying business remains robust, which may support the stock despite the GAAP loss.
Key facts
- 1GAAP net loss was $236.3 million, or $2.64 per share, for Q3 2026. scanx.trade
- 2The loss includes a $389.7 million litigation settlement charge. scanx.trade
- 3Total revenue for the quarter was $225.3 million, a 314.04% increase from Q3 2025. scanx.trade
- 4YUTREPIA net product sales were $222.7 million, up 31% from the prior quarter. scanx.trade
- 5Adjusted EBITDA amounted to $140.5 million, the fifth straight quarter of growth. scanx.trade
- 6Cash and cash equivalents stood at $396.1 million as of September 30 2026. scanx.trade
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.